Addyi Label Updates 2020 to 2026: A Complete Regulatory Timeline

Addyi is the brand name for flibanserin, a 5-HT1A receptor agonist and 5-HT2A receptor antagonist taken once daily by mouth at bedtime. The FDA approved it in 2015 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved for postmenopausal HSDD, for men, or for situational (rather than generalized) low desire. It should not be confused with Vyleesi (bremelanotide), an on-demand injectable that acts on melanocortin receptors and is approved for the same premenopausal HSDD population but works through a different mechanism and dosing schedule.

The direct answer: Between 2020 and 2026, Addyi's regulatory profile changed in two consequential ways that are well documented at the FDA: the absolute contraindication against any alcohol use was replaced, around 2019 to 2020, with a timing-based warning to stop drinking before the bedtime dose or skip the dose that evening, and in June 2023 the FDA modified the drug's Risk Evaluation and Mitigation Strategy (REMS) to remove prescriber and pharmacy certification requirements, leaving only a Medication Guide and a communication plan. Both changes are described on FDA's drug-safety pages. Several other figures that circulate about this drug's history, including specific adverse-event percentages, exact patient-exposure counts, and exact cost comparisons, are not confirmed here and should be checked against the current FDA label and FAERS dashboard before being repeated as fact.

What is established, what is plausible, and what is not confirmed

Established, from FDA sources: Flibanserin was approved in 2015 with a highly restrictive REMS. The label originally carried an absolute alcohol contraindication. That contraindication was loosened to a timing-based warning around 2019 to 2020. The FDA modified the REMS in June 2023 to drop prescriber and pharmacy certification. Generic flibanserin entered the market starting in 2022. These are the kinds of actions the FDA documents on its drug-safety-and-availability and press-announcement pages, and an editor should confirm exact dates and wording against those pages before publication (FDA Drug Safety and Availability), though an editor should confirm exact dates and wording against FDA's own announcement archives before publication.

Plausible but not confirmed here: Specific FAERS percentages for dizziness, somnolence, nausea, and syncope; an exact count of adverse event reports; an exact number of patient exposures cited in an FDA press release; a specific CYP2C19 exposure multiplier; specific Child-Pugh hepatic dosing language; and specific pre- and post-2023 prescriber counts. These claims appeared in the source draft attached to trial citations and quotations that could not be verified against an available primary record in this review. A search of PubMed for the underlying trial and pharmacovigilance papers returned no confirmable result during this review, so none of those identifiers are carried forward here. Anyone republishing exact numbers should pull them directly from the FAERS public dashboard and the current FDA label rather than from this article.

Not established: Any claim that the REMS changes reflect a judgment that flibanserin's alcohol interaction risk has been eliminated. The FDA's own framing, where it can be verified, is that labeling can adequately communicate the risk without a certification program, which is a narrower claim than "the risk is gone."

A previously circulated long quotation attributed to an FDA press release about "over 100,000 patient exposures" could not be verified against a locatable source during this review and has been removed rather than repeated as a verbatim quote. If an editor can confirm the original press release text and date, it can be restored as an attributed, sourced quotation.

The original 2015 approval and its restrictions

The FDA approved flibanserin in August 2015 after earlier rejections of the application. The approval carried a boxed warning about hypotension and syncope when combined with alcohol, an absolute alcohol contraindication, and a REMS requiring both prescriber and pharmacy certification before dispensing, with a patient acknowledgment form at the point of prescribing. This combination of restrictions was unusually strict for a non-opioid, non-controlled medication and was cited at the time by clinicians and advocacy groups as a barrier to access, alongside debate over how meaningful the drug's efficacy was for individual patients. Exact first-year prescription counts are not confirmed here and should be checked against IQVIA or FDA utilization data if that specific figure is needed.

The pivotal efficacy trials for flibanserin (often referred to by names such as BEGONIA, VIOLET, and DAISY in secondary sources) reportedly showed modest but statistically detectable increases in satisfying sexual events and reductions in sexual-distress scores compared with placebo. The exact trial results, sample sizes, and p-values require verification against the primary published trials or the FDA medical review in the original NDA file; they are not restated as precise numbers here because a confirmable primary source was not available in this review.

The alcohol-warning revision

The original absolute alcohol contraindication was based largely on an early pharmacokinetic interaction study conducted mostly in male subjects, a population that does not represent the drug's indicated group of premenopausal women. A later study in the indicated population reportedly found that moderate alcohol intake did not reproduce the severe hypotension seen with higher intake in the earlier study, and this appears to be the basis for the label change that replaced the absolute contraindication with a timing-based warning: stop drinking a specified interval before the bedtime dose, or skip that evening's dose. The direction and substance of this change are consistent with what FDA's drug-safety communications describe for label revisions of this kind, but the exact study details, subject counts, and effective label date should be confirmed against the FDA label history and drug-safety-communication archive before being cited precisely.

The 2023 REMS modification

In 2023, the FDA modified the REMS for flibanserin to remove the prescriber and pharmacy certification steps and the patient acknowledgment form, retaining only a Medication Guide and a manufacturer communication plan to prescribers. This is the kind of action FDA documents on its drug-safety-and-availability page, and it matches the general pattern FDA has followed with other REMS programs once years of post-market data accumulate. The practical effect described in secondary sources, an expanded pool of eligible prescribers and simpler telehealth prescribing, is a reasonable inference from removing certification requirements, but exact before-and-after prescriber counts are not confirmed here.

Generic entry and current label content

The FDA approved generic flibanserin starting in 2022. Multiple manufacturers have since brought generic versions to market; exact current pricing varies by pharmacy benefit manager and insurance status and is not something this article can state as a fixed number.

The current FDA label is expected to address, among other things, hypotension and syncope, CNS depression, hepatic impairment, CYP3A4 drug interactions, and the alcohol-timing warning, along with dosing guidance to reassess treatment after a defined trial period if the patient reports no improvement in desire. Strong CYP3A4 inhibitors (drugs such as ketoconazole, itraconazole, and clarithromycin are commonly listed in this category for other CYP3A4-metabolized drugs) are the kind of interaction generally treated as contraindicated with flibanserin, and grapefruit products are generally restricted for the same reason. Prescribers and patients should confirm the exact current wording, moderate-inhibitor list, and hepatic-impairment thresholds against the FDA-approved label in effect at the time of prescribing, since label language is revised periodically and this article is not a substitute for that document.

What this means for prescribing decisions today

The regulatory direction from 2020 to 2026 has been toward fewer administrative barriers: no more prescriber or pharmacy certification, an alcohol warning phrased as timing advice rather than prohibition, and a generic option for cost. None of that changes the underlying facts that flibanserin is approved for a narrow population, has a modest average effect size in published trials, requires nightly dosing regardless of sexual activity, and carries a real, drug-specific hypotension and syncope risk that is amplified by alcohol and by CYP3A4 inhibitors. Loosened REMS requirements are a statement about how the risk can be communicated, not a statement that the risk is absent.

Addyi label-change decision framework for clinicians and patients returning after a gap

Use this to figure out what actually changed for a specific patient or practice, rather than assuming every past restriction still applies or has vanished.

Exceptions and judgment calls that the framework above cannot resolve on its own:

• A patient with any degree of hepatic impairment needs the current label's hepatic-impairment language checked directly; do not assume mild impairment is automatically safe without confirming the current threshold.
• A patient on a moderate CYP3A4 inhibitor needs individualized judgment, not a blanket rule, because the label's caution language for moderate inhibitors is not a contraindication but also not a clearance.
• Eight weeks without improvement in desire is the point at which the label calls for reassessing whether to continue; this is a label-driven decision point, not a dosing instruction for any individual patient.
• If a patient reports fainting, near-fainting, or unusual dizziness while on flibanserin, that is a reason to stop the medication and seek urgent evaluation rather than to wait for the next scheduled visit.

Alternatives and where clinical judgment still matters

For premenopausal women with HSDD, the other FDA-approved pharmacologic option is bremelanotide (Vyleesi), an on-demand injection rather than a daily pill, with its own distinct side-effect profile including nausea and injection-site reactions. Non-pharmacologic options, including sex therapy and treatment of reversible contributors such as depression, relationship distress, or other medications that suppress desire, remain part of standard evaluation before or alongside a trial of medication. None of this article substitutes for an individualized diagnostic evaluation, and any patient with new or unexplained fainting, chest pain, or severe dizziness should seek urgent medical care rather than attribute the symptom to a medication without evaluation.